Identification of the ns5b s282t resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis c virus-infected patients treated with mericitabine and danoprevir

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3105-3114

  Tong, Xiao ^a   Li, Lewyn ^a   Haines, Kristin ^a   Najera, Isabel ^a  

^a Pharma Research and Early Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; DANOPREVIR; MERICITABINE; MUTANT PROTEIN; NONSTRUCTURAL PROTEIN 5B; PLACEBO; RITONAVIR; VIRUS RNA; 2'-FLUORO-2'-METHYL-3',5'-DIISOBUTYRYLDEOXYCYTIDINE; ANTIVIRUS AGENT; DEOXYCYTIDINE; LACTAM; SULFONAMIDE; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FOLLOW UP; GENE LOCUS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PYROSEQUENCING; REPLICON; VIRUS REPLICATION; WILD TYPE; ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DNA REPLICATION; DNA SEQUENCE; DRUG EFFECTS; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MALE; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; VIROLOGY;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; BASE SEQUENCE; DEOXYCYTIDINE; DNA REPLICATION; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LACTAMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PHENOTYPE; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84901263471     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02672-13     Document Type: Article

References (37)

1. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. 2011. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54:1433-1444. http://dx.doi.org/10.1002/hep.24641.
2. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364:2405-2416. http://dx.doi.org/10.1056/NEJMoa1012912.
3. Poordad F, McCone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364: 1195-1206. http://dx.doi.org/10. 1056/NEJMoa1010494.
4. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F. 2011. Response-guided telaprevir combination treatment for hepatitisCvirus infection. N. Engl. J. Med. 365:1014-1024. http://dx.doi.org/10.1056/NEJMoa1014463.
5. Jacobson IM, Dore GJ, Foster GR, Fried MW, Manns MP, Marcellin P, Poordad F, Araujo ES, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. 2013. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: efficacy in difficult-to-treat patient sub-populations in the QUEST 1 and 2 phase III trials. Hepatology 58:756A-757A.
6. Pawlotsky JM. 2006. Hepatitis C virus population dynamics during infection. Curr. Top. Microbiol. Immunol. 299:261-284. http://dx.doi.org/10. 1007/3-540-26397-7-9.
7. Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. 2010. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376:1467-1475. http://dx.doi.org/10.1016/S0140- 6736(10)61384-0.
8. Ali S, Leveque V, Le Pogam S, Ma H, Philipp F, Inocencio N, Smith M, Alker A, Kang H, Najera I, Klumpp K, Symons J, Cammack N, Jiang WR. 2008. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack crossresistance with R1479. Antimicrob. Agents Chemother. 52:4356-4369. http://dx.doi.org/10.1128/AAC.00444- 08.
9. Le Pogam S, Seshaadri A, Ewing A, Kang H, Kosaka A, Yan JM, Berrey M, Symonds B, De La Rosa A, Cammack N, Najera I. 2010. RG7128 alone or in combination with pegylated interferon-Alpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J. Infect. Dis. 202:1510-1519. http://dx.doi.org/10.1086/656774.
10. Pawlotsky JM, Najera I, Jacobson I. 2012. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir. Ther. 17:411-423. http://dx.doi.org/10.3851/IMP2088.
11. Le Pogam S, Yan JM, Kosaka A, Ji Y, Gonzaludo N, Ewing A, Klumpp K, Najera I. 2010. No evidence of drug resistance or baseline S282T resistance mutation among GT 1 and GT 4 HCV infected patients on nucleoside polymerase inhibitor RG7128 and peg-IFN/RBV combination treatment for up to 12 weeks: interim analysis from the PROPEL study. Hepatology 52:701A-702A.
12. Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, Yan JM, So SS, Klumpp K, Najera I. 2014. In vivo emergence of a novel mutant L159F/ L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J. Infect. Dis. 209: 668-675. http://dx.doi.org/10.1093/infdis/jit562.
13. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. 2011. Differential efficacy of protease inhibitors againstHCVgenotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 141:1067-1079. http://dx.doi.org/10.1053/j.gastro.2011.06.004.
14. Imhof I, Simmonds P. 2011. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 53:1090-1099. http://dx.doi.org/10.1002/hep.24172.
15. Seiwert SD, Andrews SW, Jiang Y, Serebryany V, Tan H, Kossen K, Rajagopalan PT, Misialek S, Stevens SK, Stoycheva A, Hong J, Lim SR, Qin X, Rieger R, Condroski KR, Zhang H, Do MG, Lemieux C, Hingorani GP, Hartley DP, Josey JA, Pan L, Beigelman L, Blatt LM. 2008. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob. Agents Chemother. 52:4432-4441. http://dx.doi.org/10.1128/AAC.00699-08.
16. Everson G, Cooper C, Hezode C, Shiffman ML, Yoshida E, Beltran- Jaramillo T, Ferenci P, Zeuzem S, Brunda M, Shulman N, Navarro M, Voulgari A, Najera I, Le Pogam S, Yetzer ES. 2012. Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavirboosted danoprevir/PEG-IFNa-2a/RBV in HCV genotype 1 or 4 patients: Dauphine week 12 interim analysis. J. Hepatol. 56:S466. http://dx.doi.org/10.1016/S0168-8278(12)61189-1.
17. Gane EJ, Rouzier R, Stedman C, Wiercinska-Drapalo A, Horban A, Chang L, Zhang Y, Sampeur P, Najera I, Smith P, Shulman NS, Tran JQ. 2011. Antiviral activity, safety, and pharmacokinetics of danoprevir/ ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients. J. Hepatol. 55:972-979. http://dx.doi.org/10.1016/j.jhep.2011.01.046.
18. Le Pogam S, Navarro M, Bu L, Voulgari A, Ilnicka M, Yan JM, Klumpp K. 2012. Low rate of on-treatment resistance to danoprevir boosted by ritonavir (DNVR) combined with PEG-IFNA-2a/ribavirin: 12 week interim analysis from Dauphine study. J. Hepatol. 56:S472. http://dx.doi.org/10.1016/S0168-8278(12) 61203-3.
19. Le Pogam S, Yan JM, Chhabra M, Ilnicka M, Ji Y, Zhang Y, Shulman N, Klumpp K, Nájera I. 2011. Low prevalence of danoprevir resistance identified in GT1b HCV patients with prior null response treated with danoprevir plus low-dose ritonavir plus PEGIFNa-2a(40kd)/RBV for 12 weeks. J. Hepatol. 54:S485. http://dx.doi.org/10.1016/S0168-8278(11)61229-4.
20. Lim SR, Qin X, Susser S, Nicholas JB, Lange C, Herrmann E, Hong J, Arfsten A, Hooi L, Bradford W, Najera I, Smith P, Zeuzem S, Kossen K, Sarrazin C, Seiwert SD. 2012. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrob. Agents Chemother. 56:271-279. http://dx.doi.org/10. 1128/AAC.05636-11.
21. Le Pogam S, Navarro M, Chi B, Voulgari A, Klumpp K, Najera I. 2012. Overall low rate of resistance to danoprevir (DNV) in HCV genotype (G) 1/4 patients treated with ritonavir-boosted danoprevir (DNVr) plus peginterferon alfa-2a (40KD)/ribavirin (P/R) in the DAUPHINE study. Hepatology 56:571A-572A.
22. Thompson AJ, McHutchison JG. 2009. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J. Viral Hepat. 16:377-387. http://dx.doi.org/10.1111/j.1365-2893.2009.01124.x.
23. Kieffer TL, Kwong AD, Picchio GR. 2010. Viral resistance to specifically targeted antiviral therapies for hepatitisC(STAT-Cs). J. Antimicrob. Chemother. 65:202-212. http://dx.doi.org/10.1093/jac/dkp388.
24. Lohmann V, Hoffmann S, Herian U, Penin F, Bartenschlager R. 2003. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 77:3007-3019. http://dx.doi.org/10.1128/JVI.77.5.3007-3019.2003.
25. Clark JL, Hollecker L, Mason JC, Stuyver LJ, Tharnish PM, Lostia S, McBrayer TR, Schinazi RF, Watanabe KA, Otto MJ, Furman PA, Stec WJ, Patterson SE, Pankiewicz KW. 2005. Design, synthesis, and antiviral activity of 2-deoxy-2-fluoro-2-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J. Med. Chem. 48:5504-5508. http://dx.doi.org/10.1021/jm0502788.
26. Jiang Y, Andrews SW, Condroski KR, Buckman B, Serebryany V, Wenglowsky S, Kennedy AL, Madduru MR, Wang B, Lyon M, Doherty GA, Woodard BT, Lemieux C, Do MG, Zhang H, Ballard J, Vigers G, Brandhuber BJ, Stengel P, Josey JA, Beigelman L, Blatt L, Seiwert SD. 2014. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. J. Med. Chem. 57:1753-1769. http://dx.doi.org/10.1021/jm400164c.
27. Hoffmann-La Roche Inc. 2008. Roferon-A prescribing information, revised. Hoffmann-La Roche Inc., Nutley, NJ.
28. Reeves JD, Petropoulos CJ, Huang W. 6 June 2013. Methods for the phenotypic detection of HCV inhibitor resistant subpopulations. Patent application US20130302782.
29. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. 2007. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 17:1195-1201. http://dx.doi.org/10.1101/ gr.6468307.
30. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57:289-300.
31. Chase R, Skelton A, Xia E, Curry S, Liu S, McMonagle P, Huang HC, Tong X. 2009. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors. Antiviral Res. 84:178-184. http://dx.doi.org/10.1016/j.antiviral.2009.09.003.
32. Bae A, Sun SC, Qi X, Chen X, Ku K, Worth A, Wong KA, Harris J, Miller MD, Mo H. 2010. Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob. Agents Chemother. 54:5288-5297. http://dx.doi.org/10.1128/AAC.00777-10.
33. Le Pogam S, Yan JM, Chhabra M, Ilnicka M, Kang H, Kosaka A, Ali S, Chin DJ, Shulman NS, Smith P, Klumpp K, Najera I. 2012. Characterization of hepatitisCvirus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir. Antimicrob. Agents Chemother. 56:5494-5502. http://dx.doi.org/10.1128/AAC.01035-12.
34. Hedskog C, Gontcharova V, Han B, Martin R, Miller MD, Mo H, Svarovskaia ES. 2013. Evolution of the HCV viral population from the one patient with S282T detected at relapse after sofosbuvir monotherapy, abstr A9. Abstr. Int. Workshop HIV Hepatitis Virus Drug Resist. Curative Strategies, Toronto, Ontario, Canada.
35. Verbinnen T, Jacobs T, Vijgen L, Ceulemans H, Neyts J, Fanning G, Lenz O. 2012. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays. J. Antimicrob. Chemother. 67:2327-2337. http://dx.doi.org/10.1093/jac/dks234.
36. Feise RJ. 2002. Do multiple outcome measures require p-value adjustment? BMC Med. Res. Methodol. 2:8. http://dx.doi.org/10.1186/1471-2288-2-8.
37. Kuiken C, Yusim K, Boykin L, Richardson R. 2005. The Los Alamos hepatitis C sequence database. Bioinformatics 21:379-384. http://dx.doi.org/10.1093/ bioinformatics/bth485.